Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3024 participants.
Also called NCT01401647
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 3,024 participants
- Sponsor
- Registry
-
NCT01401647
-
- Other papers using this trial's data
- Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest
- Antiarrhythmic Drugs for Nonshockable-Turned-Shockable Out-of-Hospital Cardiac Arrest: The ALPS Study (Amiodarone, Lidocaine, or Placebo)
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT01401647. Randomized; quadruple masking; primary purpose treatment. Start 2012-05 (registry gives no type); primary completion 2015-12 (actual). Results posted on 2017-01-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia
- Acronym
- ALPS
- Condition
- Cardiac Arrest
- Intervention (Drug)
- amiodarone
- Intervention (Drug)
- Lidocaine
- Intervention (Other)
- Normal saline
- Lead sponsor
- University of Washington
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator
- Canadian Institutes of Health Research (CIHR)
- Collaborator
- Heart and Stroke Foundation of Canada
- Collaborator
- American Heart Association
- Collaborator
- Defence Research and Development Canada
- Collaborator
- U.S. Army Medical Research and Development Command
Record details
- Record id
cardio:ct-nct01401647- Content hash
0f22561e8e470ce4278cb875577ef0d65c987bff664a9755d2bd3d3fef9cf96b